Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated Dosing of RO5459072 in Healthy Subjects
NCT02521610Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) and celiac disease comparing Placebo with RG7625 (2 arms). Primary endpoint: Change in concentration of 10-kilodalton (kDa) cluster of differentiation (CD) 74 intermediate (p10) in B-cells. Started Aug 2015; status: completed.
02
Drugs
petesicatib
03
Conditions
systemic lupus erythematosus (SLE)celiac disease
Beyond the preview
Go deeper on NCT02521610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521610.